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Abstract: Dupuytren’s disease (DD) is a common disease of the hand and is characterized by 
thickening of the palmar fascia and formation of tight collagenous disease cords. At present, the 
disease is incurable and the molecular pathophysiology of DD is unknown. Surgery remains 
the most commonly used treatment for DD, but this requires extensive postoperative therapy 
and is associated with high rates of recurrence. Over the past decades, more indepth explora-
tion of the molecular basis of DD has raised the hopes of developing new treatment modalities. 
This paper reviews the clinical presentation and molecular pathophysiology of this disease, as 
well as current and emerging treatment. It also explores the implications of new findings in the 
laboratory for future treatment.
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Introduction
Dupuytren’s disease (DD), also known as Dupuytren’s contracture, is a common patho-
logic condition of the hand. The hallmark of the disease is the formation of occasionally 
painful nodules in the palm of the hand and of tendon-like cords that lead to flexion 
deformities of the affected fingers. This pathology can lead to pain upon gripping, 
but most patients seek medical attention when contractures result in limitations in 
dexterity. Patients complain about not being able to put their gloves on or that they 
cannot grasp objects well. Often there are social concerns, such as embarrassment 
when shaking hands.1 Treatment is mostly offered to patients who desire correction of 
flexion deformities or to those who are bothered by the painful nodules. However, in 
the absence of a full understanding of the molecular pathology, treatment is currently 
aimed at eliminating the contracted pathologic disease tissue, without correcting the 
underlying pathophysiology. Because of this, recurrences are common and current 
work is aimed at a deeper understanding of the disease process. This review summa-
rizes the clinical presentation of the disease, reviews current and emerging treatment, 
and touches on new data regarding the molecular pathophysiology of DD. It also 
explores the implications of these advancements for future work.
Clinical presentation and anatomy
DD often occurs bilaterally, but typically affects one hand more severely than the 
other. The earliest signs of DD involve changes in the skin, such as the presence of 
pits in the skin of the palm or changes to the skin on the dorsum of the hand with the 
presence of knuckle pads or Garrod nodes.2,3Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The ring and small fingers are most often involved, 
although the other fingers and thumb may also be affected.3 
The disease is thought to progress from a palmar nodule into a 
longitudinal cord. These cords seem to follow normal palmar 
fascial structures which in their healthy states are designated 
as “bands”. As the cord matures, it contracts and becomes 
more fibrotic, taking on a more distinct tendon-like appear-
ance and resulting in flexion contractures of the digits.4
In the palm, the most common cord is the precentral 
cord, which arises from the precentral band of the palmar 
fascia and typically results in a flexion deformity of the 
metacarpophalangeal (MCP) joint. Other cords in the palm 
include the vertical and natatory cords (arising respectively 
from the vertical bands of Legueu and Juvara and the nata-
tory ligaments), although these are less common than the 
precentral cord.5
In the fingers, the most common cords are the central, 
lateral, and spiral cord.4 The central cord is an extension of 
the precentral cord that forms in the midline of the fingers 
and attaches to the flexor tendon sheath. This cord can cause 
deformities in the MCP joint and proximal interphalangeal 
(PIP) joint. The lateral cord is a continuation of the bifurcated 
precentral cord and is considered the pathologic state of the 
lateral digital sheath. Unlike the central cord, it attaches to 
the skin or to the tendon sheath near Grayson’s ligament. This 
cord usually results in deformities of the PIP joint, but can 
also affect the DIP joint. The spiral cord is also an extension 
of the precentral cord that starts off deep to the neurovascular 
bundle and distal to the MCP joint. In the digit, the cord 
advances lateral to the neurovascular bundle to involve the 
lateral digital sheath and then superficial to the neurovascular 
bundle to involve Grayson’s ligament. In doing so, the cord 
wraps itself around the neurovascular bundle, which causes 
the superficial, proximal, and central displacement of the 
neurovascular bundle when finger contractures are produced. 
This displacement puts the neurovascular bundle at risk of 
damage during surgery.3
Prevalence and risk factors
DD is considered an inherited dominant condition with vari-
able penetrance, affecting males more often than females.6 
Typically, disease onset is in the fourth or fifth decade of life 
in males, while the disease tends to develop later in life for 
females.6,7 Although primary DD is more prevalent in males, 
the probability of recurrence is approximately equal between 
the sexes after surgery.6 DD has been traced to a population 
of Germanic and Celtic tribes who migrated across Northern 
Europe to Scandinavia and to the British Isles. From there, 
the disease was brought by emigrants to the New World, 
including Australia and North America. DD is less common 
in other parts of the world, such as Southern Europe, South 
America, and Asia,8 although in certain populations within 
this area, specifically Japan and Taiwan, higher prevalence 
rates have been reported.9 In Iceland, the prevalence of DD 
can be as high as 40% in males over 70 years.10
In 1963, Hueston first described a “Dupuytren’s 
  diathesis”, a term which describes factors that would 
strongly predict disease severity and disease recurrence 
after treatment.11 Patients of Northern European descent, 
those who present at a younger age of onset, and those who 
have a positive family history of DD have an increased 
probability of developing the condition, as well as having a 
more aggressive disease progression. Similarly, patients who 
have bilateral hand involvement and ectopic lesions (such as 
knuckle pads, plantar fibromatosis [Lederhosen disease], or 
penile fibromatosis [Peyronie’s disease]) are more likely to 
have aggressive disease progression and an increased risk of 
recurrence. The severity of a patient’s disease presentation 
continues to be an important factor in the management of this 
disease, and recently the statistical risk for disease recurrence 
based on these diathesis factors has been calculated.12
In addition to genetic factors, a number of comorbidities 
and socioenvironmental factors play a role in this condi-
tion. Studies have suggested that DD clusters in patients 
with certain underlying health conditions, such as diabetes 
mellitus13,14 and epilepsy.15 Lifestyle risk factors that have 
been associated with DD include smoking and high alcohol 
consumption.16–18 Other factors, such as manual labor,19 hand 
or wrist trauma,20 and a history of repetitive hand vibrations21 
have also been associated with the disease. The contributions 
of these factors remain controversial, however, and other 
studies have been unable to identify any correlation.22
Treatment
While the current research focus is on the identification 
of potential molecular therapies for DD management, the 
most widely practiced intervention is still surgical resection 
of the disease cords.23,24 Surgical treatment is based on the 
simple premise that the disease cords prevent the fingers 
from extending and that excision of the diseased tissue 
leads to “freeing-up” of the joints and return of range of 
motion. Review of the surgical results, however, often shows 
incomplete return of range of motion and considerable rates 
of recurrence. Nonetheless, because surgery still forms the 
mainstay of treatment, we will include surgical treatment of 
DD in this review.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Surgery for Dupuytren’s disease
Surgical intervention is typically considered when the con-
tracture significantly affects hand function. This is usually 
where the MCP and/or PIP flexion contracture exceeds 30°, 
and many surgeons use a simple assessment such as the 
“table-top test” to determine appropriateness for surgery. 
This “table-top test” dictates that once a hand can no longer 
be placed flat on the table, consideration should be given to 
surgical release.25
There are a number of surgical variations available to 
address finger contractures in DD. Multiple options to expose 
the fascia have been described, including longitudinal midline 
incisions closed with Z-plasties, Bruner-type zigzag inci-
sions, and multiple transverse incisions.26 Most operations 
for the correction of DD contractures involve some form of 
palmar fasciectomy, and fasciectomy can be divided into 
local, regional, and radical fasciectomy. Of the three, local 
fasciectomy is the least invasive, and involves resection 
of segments of the disease cord, thereby releasing finger 
contracture. Because residual disease tissue remains in the 
hand following the local fasciectomy procedure, the chance 
of recurrence is high.3 A more extensive approach is regional 
or partial fasciectomy, a technique involving the removal of 
as much of the affected fascia as possible.27 Radical or total 
fasciectomy is a more invasive procedure, involving the 
excision of the palmar and digital fascia. This technique is 
associated with an increased risk of surgical complications 
and does not have lower recurrence rates when compared 
with partial fasciectomy.28
For less advanced disease involving only palmar cords, 
the use of fasciotomy has been advocated. Fasciotomy is 
a technique used to release contractures by dividing the 
disease cord without the excision of the diseased tissue.29 
As the diseased tissue is not removed, the risk of disease 
recurrence is relatively high.30 The closed procedure, often 
referred to as needle fasciotomy or needle aponeurotomy, 
involves the placement of a needle adjacent to the cord, and 
“slicing” or “piercing” of the disease cord with the sharp bev-
eled edge of the needle to release the contracture.31,32 While 
this procedure is minimally invasive in nature, most surgeons 
still believe that it should be used with caution because it 
puts the flexor tendons and nerves at risk of being severed 
during surgery.32 It is currently believed to have a role only 
in the management of mild to moderate MCP contractures. 
An alternative approach to the closed fasciotomy is the open 
fasciotomy procedure. This approach involves creating an 
incision in the palm of the hand, allowing visualization of the 
disease cord. The cord can then be severed, thereby releasing 
the contracture. This procedure is less invasive than closed 
fasciotomy, but has the advantage of reducing the risk of 
damage to the nerves in the hand because it allows for direct 
visualization of the disease cord.
For management of aggressive or recurrent disease, 
dermofasciectomy has been recommended. This extensive 
technique involves excision of the diseased fascia en bloc 
with the overlying skin, and subsequent use of skin grafts to 
close the skin.33,34 Compared with fasciectomy alone, der-
mofasciectomy offers a lower chance of disease recurrence. 
Because of this, despite longer postoperative rehabilitation, 
this technique is sometimes recommended for younger 
patients or for those with Dupuytren’s diathesis and a history 
of aggressive disease recurrence.
To improve long-term results, splinting is prescribed as 
a postoperative physical therapeutic modality.35 While the 
effectiveness of splinting without surgery is dubious, most 
surgeons would still advocate it as an adjunct to surgery to 
maximize finger extension and function.3,36 After the acute 
wound healing stage has passed, most surgeons would also 
continue night splinting to maintain extension in the remodel-
ing phase of wound healing.
Recurrence rates following surgery remain high and, 
recurrence rates increase with longer follow-up periods.3 
Complications of surgery include digital nerve injury, skin 
flap loss, wound healing problems, infection, hematoma, 
and postoperative stiffness. Occasionally patients develop a 
regional complex pain syndrome or exhibit prolonged post-
operative inflammation requiring prolonged hand therapy.37 In 
the end, some patients with a history of multiple recurrences 
or surgery-associated complications opt for amputation of the 
affected finger(s) rather than undergo further surgery.
Biologic treatment approaches
Because of the high rates of disease recurrence and inher-
ent risks of surgical intervention, a shift in focus of recent 
research in DD has been towards identifying potential 
molecular targets for nonsurgical alternative therapies.
The most straightforward nonsurgical treatment of DD 
has been to accomplish the same as surgical removal of the 
disease cords but by enzymatic digestion of the cord. This 
approach has been tried for a number of decades with vari-
able success. In 1971, Hueston reported that enzymatic fas-
ciotomy can achieve similar outcomes to surgical fasciotomy, 
and suggested that it may be an appropriate alternative for 
selected patients.38 Enzymatic fasciotomy is the injection of 
a cocktail of proteolytic and anti-inflammatory enzymes, 
specifically trypsin, hyaluronidase, and lidocaine, to disrupt Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the   collagenous nature of the disease   environment.38 This 
  injection is followed by physical manipulation to straighten 
the digits, breaking the disease cord and releasing the 
  contracture. Because the disease cords are primarily composed 
of Type I and Type III collagen,14,39,40 more recently, inves-
tigators have been starting to use a mixture of clostridium-
derived collagenases, Clostridium hystolyticum Type I and 
Type II, which specifically target the NH3 and COOH termi-
nals and internal peptide residues, respectively, in collagen 
fibers. These enzymes belong to the matrixin subgroup of 
the metalloproteinases, requiring Zn2+ and Ca2+ for activity. 
A number of studies have now provided data that collagenase 
injection into disease cords improves finger contractures and 
improves joint mobility in advanced disease.14,41–44 Marketed 
as Xiaflex® (Auxilium Pharmaceuticals, Inc.), these injections 
can be considered as a nonoperative alternative to surgery. 
However, like surgery, this approach targets a result of the 
disease process, ie, excess collagen deposition, rather than the 
cause of the disease, which is thought to be   hyperproliferative, 
contractile, and collagen-producing disease cells within the 
palmar fascia. Finally, because collagenase does not act spe-
cifically on the disease cord structure, the long-term safety 
of injecting this enzyme into other structures of the hand 
that also contain collagen, such as tendons, ligaments, and 
neurovascular bundles, should also be considered. The current 
evidence suggests that collagenase C. hystolyticum specifi-
cally targets fibrillar collagens such as Type I and Type III 
(but not Type IV) collagen, the primary collagen constituent 
of blood vessels. The long-term rate of recurrence, as well 
as safety of collagenase treatment of DD, is currently being 
evaluated in several Phase III trials.
The use of corticosteroid injections has been advocated 
as a treatment for early disease or for painful nodules. 
Intralesional injection of a corticosteroid directly into palmar 
nodules can result in softening and reduction of pain.45 This 
correlates with molecular studies which show that steroids 
can function as an antifibrotic agent, reducing cell prolifera-
tion, while inducing apoptosis or programmed cell death.46,47 
The potential side effects of steroid use are skin depigmen-
tation and dermal atrophy from collagen degradation.48,49 
Rarely, flexor tendon ruptures have been described.
Another biologic agent to address the observed   cellular 
proliferation and inflammation in DD is δ-interferon.50 
Molecular studies on cells derived from DD patients show 
that δ-interferon can reduce cell proliferation, collagen 
production, and the expression of α-smooth muscle actin, a 
predominant isoform of actin found in contractile cells called 
myofibroblasts.51,52 While there have been a number of   studies 
showing the potential benefits of δ-interferon in the treatment 
of DD, most of these studies have been conducted in vitro 
and whether these translates into clinical improvements is 
largely unknown. One small pilot study reported a decrease 
in the size of the lesion(s) associated with DD and that, at 
least in hypertrophic scar tissue, treatment with δ-interferon 
resulted in a decrease of α-smooth muscle actin expression 
and myofibroblast formation by immunohistochemistry.50 
This study was not specific to DD, and included only four 
patients with DD in the hand, while the remainder presented 
with hypertrophic scars or plantar fibromatosis. Larger stud-
ies are required to determine whether the therapeutic benefits 
of δ-interferon in cell cultures in laboratories can translate 
into improvements in hand function in the clinical setting.
DD has been viewed as an exaggerated wound healing 
response53 and, since the wound healing response includes 
Type I and Type III collagen deposition, knowledge from 
this process has been applied to the study of DD. In this light, 
other biologic agents that may offer therapeutic benefits in 
DD, including agents that may affect the ratio between a 
group of specific collagenases found in wound healing, ie, 
matrix metalloproteinases (MMPs) and their inhibitors (tis-
sue inhibitors of metalloproteinases, TIMPs). MMPs and 
their inhibitors regulate extracellular matrix (ECM) turn-
over and function. Studies have found correlations between 
MMP expression and DD progression and recurrence,54 and 
the MMP:TIMP ratio in DD fascia has been found to be 
  abnormal.55 Treatment of cancer patients with a synthetic 
TIMP has been shown to result in DD,56 but other studies have 
shown that the use of ilomastat, a broad MMP inhibitor, leads 
to decreased mechanical tension generated by disease nodule 
and cord cells.57 The proposed pharmacologic manipulation 
of the MMP:TIMP ratio and how this affects DD54,57–59 will 
require further study to determine the clinical applicability 
and potential effectiveness of such treatments on improving 
hand and joint function.
Recent molecular studies
There is a general consensus that a greater understanding of 
the molecular mechanism of DD will lead to the creation of 
more specific and effective treatment alternatives. The study 
of the cellular behavior of cells in diseased fascia, however, is 
hampered by the fact that the treatment of choice in the early 
stages of DD is observation. The genetic and molecular study 
of early-stage DD cells is thus not always feasible. The main 
tool to discern cellular abnormalities has been to evaluate the 
abnormal biologic behavior of DD cells obtained from surgi-
cal resection and to compare this with cells obtained from   Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  phenotypically normal palmar fascia or cells obtained from 
carpal tunnel release patients. This type of study using differ-
ential gene expression analysis, combined with molecular and 
functional studies of disease tissues and cells, has helped iden-
tify a number of putative abnormal mediators in DD. Several 
dysregulated genes in DD encode secreted ECM proteins,60–64 
and these may play a role in disease progression or recurrence. 
While structural components of the ECM, such as collagens, 
laminin, fibronectin, and elastin are altered in DD,65,66 recent 
work has also identified proteases, including A Disintegrin 
and Metalloprotease (ADAM)-12, proteoglycans (notably 
PRG4), and “matricellular” components, including tenascin C 
and periostin, as well as specific members of the MMP family 
(MMP-2 and MMP-9) mentioned earlier, as being abnormally 
regulated.61,62,64 We and others have demonstrated that perios-
tin is abundant in the ECM of DD nodules and cords60,61,64,67 
and we have also shown that periostin induces the prolif-
eration and apoptosis of phenotypically normal fibroblasts 
derived from the palmar fascia adjacent to the DD cord, and 
myofibroblast differentiation of DD cells.64 ECM molecules, 
such as periostin, which initiate a differential response in DD 
cells and adjacent fibroblasts, may have different roles in DD 
progression and recurrence. The functional characterization of 
these ECM proteins, therefore, may identify novel therapeutic 
targets to prevent DD recurrence.68,69
Along these lines, our laboratory has chosen to focus 
on dysregulation of the Wnt-β-catenin pathway, because we 
first identified elevated total and tyrosine-phosphorylated 
β-catenin levels in DD.70 In our studies, we also found that the 
ECM plays a role in expression of the disease phenotype.65,66 
The current hypothesis that we are working on is that DD 
cells modify their extracellular environment by secreting (or 
depleting) molecules that promote (or inhibit) myofibroblast 
differentiation in their collagenous ECM. Perhaps, when 
this modified ECM is left behind after surgical resection 
of the DD cord, there is the potential for these secreted 
factors to activate fibroblasts resident in the adjacent fascia 
to differentiate into myofibroblasts and promote disease 
recurrence.71 Currently, we are testing potential mediators of 
myofibroblast development by incorporating them into col-
lagen substrates to mimic the in vivo environment and, in this 
way, we have demonstrated that a collagen-enriched substrate 
modifies transforming growth factor-beta (TGF-β) signaling 
in DD cells.72 We have also demonstrated that periostin, a 
TGF-β-induced and abundant component of the DD ECM, 
promotes myofibroblast differentiation of primary DD cells 
and have uncovered evidence of insulin-like growth factor 
(IGF) and IGF binding protein (IGFBP) changes in DD (see 
Figure 1). The latter interactions are intriguing from several 
perspectives. Firstly, ADAM-12, which is abundant in the 
Latent TGFβ1/2 activated by
stress/tension of the ECM
TGFβ1 or 2
Periostin
Extra-cellular
cytoplasm
SMAD4
SMAD4
SMAD2
SMAD3
FAK
Src
Talin
Paxillin
Vinculin
Pl3 Kinase
Akt/PKB
Glycogen
Synthase
Kinase-3β
Other ECM
associated
factors
ECM stress/tension
Myofibroblast
differentiation
ERK1/2
Type 1/2 TGFβ
receptor Receptor
activation
Figure 1 Proposed scheme in which TGF-β signalling, ECM stress tension, and/or other ECM-associated factors may lead to dysregulation of myofibroblast differentiation. 
These pathways seem to be involved in the molecular pathogenesis of Dupuytren’s disease and targeted interruption of abnormal signalling components may lead to future 
treatment approaches. 
Abbreviations: eCM, extracellular matrix; TGF-β, transforming growth factor-beta.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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DD tissue, has been shown to cleave a subset of IGFBPs and 
release IGFs to stimulate cell growth and proliferation73,74. 
In parallel, another IGFBP that is not a target of ADAM-12, 
IGFBP-6, has been shown to be specifically and potently 
downregulated in desmoid tumors75 and DD (our unpublished 
data) by TGF-β signaling. Finally, IGF and IGFBP levels are 
consistently dysregulated in diabetes,76–79 a metabolic condi-
tion frequently linked to DD predisposition.6,80,81 How all these 
findings will translate into clinical treatment is as yet unclear, 
but delineation of the abnormal molecular pathophysiology of 
DD is necessary to design rational molecular treatment meth-
ods. Moreover, while DD is a difficult clinical problem in its 
own right, DD is associated with other fibroproliferative dis-
eases, including Peyronie’s disease,60,82 Lederhose disease,83,84 
frozen shoulder syndrome (adhesive capsulitis),85–87 and des-
moid tumor (aggressive polyfibromatosis).88 Research into the 
molecular pathogenesis of these diseases has shown that many 
of these disorders are characterized by dysregulated cellular 
proliferation and myofibroblast differentiation. Therefore, 
identification of molecules that induce myofibroblast develop-
ment in DD may have broad consequences for the treatment 
of these other diseases and further research into the molecular 
pathogenesis of DD remains important.
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